Sign up
Log in
MARKET
NVO
NVO
Novo-Nordisk A/S
NYSE
126.73
-1.13
-0.88%
After Hours: 126.90 +0.17 +0.13% 19:59 07/26 EDT
OPEN
126.86
PREV CLOSE
127.86
HIGH
128.26
LOW
126.36
VOLUME
3.18M
TURNOVER
0
52 WEEK HIGH
148.15
52 WEEK LOW
77.03
MARKET CAP
564.56B
P/E (TTM)
44.00
1D
5D
1M
3M
1Y
5Y
1D
FDA issues warning on compounded versions of Novo Nordisk's semaglutide
U.S. FDA issues warning on compounded versions of Novo Nordisk's semaglutide. The agency says it has received reports of adverse events associated with the drug. The drug is the active ingredient in Novo's weight loss drug Wegovy and type 2 diabetes med Ozempic.
Seeking Alpha · 7h ago
Novo Nordisk’s ($NVO) Wegovy Gets EU Support to Expand Its Use
TipRanks · 8h ago
UPDATE 1-US FDA warns of dosing errors with compounded versions of Novo's weight loss drugs
US FDA warns of dosing errors with compounded versions of Novo's weight loss and diabetes drugs. Reports of adverse events may be related to overdoses due to patients incorrectly self-administering the drugs. FDA has received reports of reports of patients miscalculating doses.
Reuters · 11h ago
UPDATE 2-US FDA flags dosing risks from compounded versions of Novo's weight-loss drug
US FDA flags dosing risks from compounded versions of Novo's weight-loss and diabetes drugs. Reports of adverse events may be related to overdoses due to patients incorrectly self-administering the drugs. The drugs may contain additional ingredients and may contribute to potential medication errors. The FDA has also expressed concerns about fake versions of other drugs.
Reuters · 11h ago
Novo Nordisk: Better Buying Opportunities Ahead
Seeking Alpha · 11h ago
BRIEF-FDA Alerts Health Care Providers, Patients Of Dosing Errors Related To Compounded Injectable Semaglutide Products
FDA Alerts Health Care Providers, Patients of Dosing Errors Related to Compounded Injectable Semaglutide Products. FDA says errors may be related to overDOSES from DOSing errors of the products. Some patients have reported mis-dosing, FDA says.
Reuters · 12h ago
FDA Alerts Health Care Providers, Compounders, And Patients Of Dosing Errors With Compounded Injectable Semaglutide Products; Reports Of Adverse Events, Including Hospitalizations, Due To Overdoses From Miscalculation And Self-Administration Errors
Benzinga · 12h ago
Artisan Global Opportunities Fund Q2 2024 Commentary
Seeking Alpha · 15h ago
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.